-
A ranar 22 ga Janairu, 2025, "Maganin Yanayi" ta buga sakamakon Akeso wanda aka samar da maganin rigakafi na PD-1/CTLA-4 bisa ka'ida tare da oxaliplatin da capecitabine don maganin farko na cututtukan ciki ko na gastroesophageal da ba a iya cirewa ba...Kara karantawa»
-
A ranar 8 ga Janairu, 2025, Hukumar Kayayyakin Lafiya ta Kasa ta China (NMPA) ta amince da PADCEVTM (enfortumab vedotin) tare da KEYTRUDA (pembrolizumab) ga manya marasa lafiya da ke fama da cutar kansa ta urothelial (la/mUC). Amincewar NMPA na enfortumab vedotin a cikin tsefe...Kara karantawa»
-
A ranar 17 ga Fabrairu, 2025, Innovent Biologics ta sanar da cewa furotin na farko na PD-1/IL-2α-bias na haɗin gwiwar rigakafi, IBI363, ya sami na biyu na Tsarin Sauri (FTD) daga Hukumar Abinci da Magunguna ta Amurka (FDA). Wannan naɗin ya shafi maganin da ba za a iya cirewa ba, ...Kara karantawa»
-
A ranar 16 ga Janairu, 2025, IMPACT ta sanar da cewa Senaparib Capsules (派舒宁®) ta sami izinin tallatawa a China daga Hukumar Kayayyakin Lafiya ta Kasa (NMPA) a matsayin maganin da ake amfani da shi na lokaci guda don kula da manya marasa lafiya da ke fama da cutar epithelial mai tsanani (FIGO Stages III da IV)...Kara karantawa»
-
A ranar 7 ga Fabrairu, 2025, Sichuan Kelun-Biotech Biopharmaceutical ta sanar da amincewa da allurar Cetuximab N01 daga Hukumar Kayayyakin Lafiya ta Kasa don magance cutar kansar hanji (mCRC) a China. Amincewar ta dogara ne akan wani babban bincike na asibiti na mataki na uku...Kara karantawa»
-
A ranar 10 ga Fabrairu, 2025, CARsgen Therapeutics ta sanar da cewa mutum na farko da aka yi wa magani da maganin allogeneic BCMA CAR-T wanda aka haɓaka akan dandamalin THANK-u Plus™, ya sami cikakken amsawa (sCR) da ƙarancin rashin lafiyar sauran cututtuka (MRD) a kimantawar Rana ta 28. An haɓaka a cikin gida...Kara karantawa»
-
A ranar 29 ga Janairu, 2025, wata ƙungiyar bincike ta ƙasar Sin ta buga wani kasidar da aka yi wa taken "Neoadjuvant pyrotinib da trastuzumab a cikin HER2 positive nono cancer without response da wuri (NeoPaTHer): tasiri, aminci, da kuma nazarin alamar halitta na wani bincike mai yiwuwa, mai cibiya da yawa, wanda aka daidaita martani" a cikin...Kara karantawa»
-
A ranar 26 ga Janairu, 2025, Cibiyar Kimanta Magunguna (CDE) ta Hukumar Kayayyakin Lafiya ta Kasa ta kasar Sin ta sanar da cewa allurar LM-108 an yi ta ne don a hada ta a cikin maganin ciwace-ciwacen da suka yi tsanani wadanda ke da rashin kwanciyar hankali na microsatellite (MSI-H) ko kuma lahani na gyara mara daidai (dMMR)...Kara karantawa»
-
A ranar 20 ga Janairu, Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ta amince da sabuwar hanyar hada maganin cisplatin da gemcitabine mai kama da monoclonal antibody tagitanlimab (wanda a da ake kira KL-A167) don maganin cutar kansa ta nasopharyngeal (NPC) mai sake dawowa ko kuma metastatic. ...Kara karantawa»
-
A ranar 16 ga Janairu, 2025, Hukumar Kula da Kayayyakin Lafiya ta Kasa (NMPA) ta amince da amfani da sabon magani (NDA) na limertinib don maganin manya marasa lafiya da suka kamu da cutar kansar huhu ta EGFR T790M da aka canza ta hanyar ƙwayoyin cuta (NSCLC) ko kuma waɗanda suka kamu da cutar. Game da Limertinib Limertinib ...Kara karantawa»
-
A ranar 8 ga Janairu, Cibiyar Kimanta Magunguna (CDE) ta Hukumar Kula da Kayayyakin Lafiya ta Kasa (NMPA) ta ba da izinin Nadin Maganin Breakthrough Therapy (BTD) don IBI343, wani magani mai inganci wanda zai iya zama mafi inganci a cikin TOPO1i anti-CLDN18.2 ADC, a matsayin magani ɗaya don maganin cutar pancr mai ci gaba ta CLDN18.2...Kara karantawa»
-
A ranar 8 ga Janairu, 2025, Cibiyar Nazarin Magunguna (CDE) ta Hukumar Kayayyakin Lafiya ta Kasa (NMPA) a China ta ba da 9MW2821 a matsayin Naɗin Maganin Farko (BTD). An ba da 9MW2821 tare da toripalimab, wani maganin rigakafi na monoclonal anti-PD-1, don magani - wanda ba shi da wahala, wanda ba a iya gano shi ba...Kara karantawa»
Cibiyar likitanci ta haɗin gwiwa ta Asibitin Ciwon Daji na Beijing